Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The company’s AN9025 will shortly enter phase 1.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
A more comprehensive dataset on JANX007 sends the group’s stock down.
But the group still hopes to get IGV-001 approved based on overall survival data.
The agency approved eight oncology products over the month.
